INmune Bio Q3 net loss $8.6M; XPro Phase II AD trial advances, INKmune on track

Inmune Bio, Inc.

2023-Q3 EPS reported -$1.20 revenue$127,000

Net loss $8.6M vs $7.7M YoY; R&D $6.0M; cash $41.8M as of Sept 30.
MHRA authorized XPro Phase II trial in early AD; recruitment increasing; top-line results expected end-2024.
FDA clinical hold on XPro for CNS expected to be lifted by end-2023.
INKmune Phase I/II in mCRPC to enroll first patient by year-end 2023; LAUREL trial in MDS/AML third site active.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

Inmune Bio, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 1, 2023, INmune Bio Inc. (the “Company”), issued a press release announcing the Company’s financial results for the quarter ended September 30, 2023 and providing a business update.

View on SEC.gov

Browse all earnings releases →

Inmune Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-082184

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.